Case Studies

Challenge: A pharmaceutical client asked Alacrita to assess a early-stage biotech company developing an orally-available agent for treating various autoimmune conditions. The pharma company was...

Challenge: A pharmaceutical company was actively searching for strategic partnering opportunities to expand its pipeline and had commissioned Alacrita to conduct a comprehensive pre-due diligence...

Challenge: A pharmaceutical company with an established gene-therapy franchise wanted to expand its oncology pipeline through external licensing. Among several options, the deal team had identified...

Challenge: A mid-cap pharmaceutical company exploring licensing and co-development opportunities in women’s health identified a promising early-stage startup. With limited internal resources...

Challenge: A generalist investment fund with limited experience in the pharmaceutical sector was evaluating a co-investment opportunity in an early-stage therapeutic project targeting novel...

Challenge: Our client, a private equity-backed specialty pharmaceutical company experiencing rapid growth through mergers and acquisitions, was actively evaluating several late-stage development...

Challenge: A leading U.S. children’s hospital commissioned an independent review of a novel therapeutic approach for rare neonatal diseases. The principal investigator (PI) - a highly regarded,...

Challenge: A privately held US-based biotech company specializing in pain therapeutics had developed a cutting-edge drug discovery platform utilizing multi-omic, tissue-specific datasets. This...

Synopsis For Technology Transfer Offices (TTOs), evaluating and prioritizing intellectual property (IP) portfolios is a critical step in determining the best allocation of internal funding and...

Challenge: An AI-driven drug discovery company requested an expert third party assessment of the attractiveness and risks of a particular discovery strategy focused on a dual tyrosine kinase...

Challenge: A mid-sized pharmaceutical company was considering the option of expanding into developing gene therapies for CNS diseases. Alacrita was asked to help them evaluate and prioritize the...

Challenge: An early-stage biotech company asked Alacrita to identify drug program assets that had been discontinued from further development due to neutralizing antibodies (Nabs) but not due to...